The 9 analysts offering 12-month price forecasts for Travere Therapeutics Inc have a median target of 42.00, with a high estimate of 49.00 and a low estimate of 24.00. The median estimate represents a +68.61% increase from the last price of 24.91.
The current consensus among 10 polled investment analysts is to Buy stock in Travere Therapeutics Inc. This rating has held steady since March, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.92
Reporting Date Aug 10
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.